- Home
- SOR vs RGNX Comparison
SOR vs RGNX Comparison
Compare SOR & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOR
- RGNX
- Stock Information
- Founded
- SOR 1968
- RGNX 2008
- Country
- SOR United States
- RGNX United States
- Employees
- SOR N/A
- RGNX N/A
- Industry
- SOR Investment Managers
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SOR Finance
- RGNX Health Care
- Exchange
- SOR Nasdaq
- RGNX Nasdaq
- Market Cap
- SOR 348.7M
- RGNX 387.0M
- IPO Year
- SOR N/A
- RGNX 2015
- Fundamental
- Price
- SOR $41.63
- RGNX $6.76
- Analyst Decision
- SOR
- RGNX Strong Buy
- Analyst Count
- SOR 0
- RGNX 9
- Target Price
- SOR N/A
- RGNX $32.89
- AVG Volume (30 Days)
- SOR 16.2K
- RGNX 1.0M
- Earning Date
- SOR 01-01-0001
- RGNX 05-07-2025
- Dividend Yield
- SOR 7.24%
- RGNX N/A
- EPS Growth
- SOR N/A
- RGNX N/A
- EPS
- SOR 6.50
- RGNX N/A
- Revenue
- SOR N/A
- RGNX $83,328,000.00
- Revenue This Year
- SOR N/A
- RGNX $285.14
- Revenue Next Year
- SOR N/A
- RGNX N/A
- P/E Ratio
- SOR $6.41
- RGNX N/A
- Revenue Growth
- SOR N/A
- RGNX N/A
- 52 Week Low
- SOR $36.41
- RGNX $5.62
- 52 Week High
- SOR $42.75
- RGNX $21.19
- Technical
- Relative Strength Index (RSI)
- SOR 44.80
- RGNX 41.59
- Support Level
- SOR $41.27
- RGNX $7.96
- Resistance Level
- SOR $42.50
- RGNX $8.35
- Average True Range (ATR)
- SOR 0.78
- RGNX 0.65
- MACD
- SOR 0.02
- RGNX -0.04
- Stochastic Oscillator
- SOR 28.38
- RGNX 13.21
About SOR Source Capital Inc.
Source Capital Inc is a diversified, closed-end management investment company. The investment objective of the company is to seek maximum total return for Common shareholders from both capital appreciation and investment income to the extent consistent with the protection of invested capital.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.